Early Use of Biologics Reduces Healthcare Costs in Crohn's Disease: Results from a United States Population-Based Cohort.

BACKGROUND: Early initiation of biologics in moderate-to-severe Crohn's disease (CD) may significantly alter disease progression, resulting in better patient outcomes. Limited real-world data exist on the impact of early biologic use in patients with CD in the United States. AIMS: We aimed to characterize biologic initiation and subsequent healthcare resource utilization (HCRU) in adults with recently diagnosed CD. METHODS: Patients with CD who initiated biologic treatment within 2 years of diagnosis (index date) were identified from medical and pharmacy claims (Merative L.P. MarketScan Database from 2010 to 2016) and classified as early (≤ 12 months post-index) or late (> 12-24 months post-index) biologic initiators. Propensity score matching balanced patient characteristics up to 1 year post-index. Differences in HCRU frequency and costs 1-2 years post-index were compared between the matched groups. RESULTS: After propensity score matching, 672 pairs of early and late biologic initiators were identified. Patients who initiated biologics early had fewer outpatient visits (15.5 vs 19.8, 95% confidence interval [CI] for difference: 2.7, 6.1) and lower total medical costs ($13,646.20 vs $22,180.70, 95% CI for difference: 4748.9, 12,320.1) 1-2 years post-index than late biologic initiators. Early biologic initiators had higher medication costs 1-2 years post-index ($33,766.30 vs $30,580.70, 95% CI: 546.1, 5825.1) but lower combined medical and medication costs ($47,412.50 vs $52,761.50, 95% CI: 801.5, 9896.40). CONCLUSIONS: While biologic treatments are costly, patients initiating biologics sooner after diagnosis appear to have better HCRU outcomes and require fewer healthcare resources at 1-2 years post-index, potentially leading to overall cost savings.

Adherence and persistence among multiple sclerosis patients after one immunomodulatory therapy failure: retrospective claims analysis.

INTRODUCTION: There are no published data on patient adherence to, and persistence with, disease-modifying therapies (DMT) for multiple sclerosis (MS) after one immunomodulatory failure. The present study compares secondline DMT adherence and persistence among patients with MS. METHODS: Patients with MS initiating a second-line treatment with natalizumab, intramuscular interferon beta-1a (i.m.-IFNß-1a), subcutaneous (s.c.) IFNß-1a, interferon beta-1b (IFNß-1b), and glatiramer acetate (GA) from January 1, 2006 to October 4, 2008 were identified from a retrospective claims database associated with a large US health plan. Adherence was measured with medication possession ratio (MPR); adherence indicated MPR ≥ 0.80. Persistence was measured as time until a minimum 60-day gap in second-line therapy. Adherence and persistence were modeled with logistic and Cox proportional hazard regressions, respectively. RESULTS: The study population comprised 1381 patients. Multivariate analysis showed that the odds of adherence were significantly higher in the natalizumab cohort compared with all other second-line cohorts. The natalizumab cohort was more likely to be persistent compared with the i.m.-IFNß-1a and IFNß-1b cohorts. CONCLUSION: The natalizumab cohort was more adherent compared with the other second-line DMT cohorts, likely due in large part to active physician involvement and monitoring. Adherence to DMT, even after first-line failure, is critical to achieving optimal therapeutic benefit.

The effects of duration and frequency of Achilles tendon stretching on dorsiflexion and outcome in painful heel syndrome: a randomized, blinded, control study.

The American Orthopedic Foot and Ankle Society recommends at least six months of nonsurgical treatment before considering surgical intervention for painful heel syndrome. Achilles tendon stretching exercises are consistently reported to be one of the more effective nonsurgical modalities for treatment of painful heel syndrome. However, the optimal duration and frequency of the exercises has not been reported. The purpose of this study was to evaluate and compare the effectiveness of sustained and intermittent Achilles tendon stretching for the relief of pain associated with painful heel syndrome. This prospective, randomized, blinded study was performed from May 1997 to July 2000. A total of 94 people (122 affected feet) fit the inclusion criterion and agreed initially to participate in a treatment study group. To achieve our purpose, study participants were randomized into two stretching groups. One group performed sustained Achilles tendon stretches (three minutes, three times daily), the other performed intermittent stretches (five sets, 20 seconds each, two times daily). Participants were evaluated once a month for a period of four months subsequent to diagnosis. At each monthly visit, participants completed subjective questionnaires about their pain. Also, a physical therapist measured each participant's Achilles tendon flexibility. The study determined that both sustained and intermittent Achilles tendon stretching exercises increase Achilles tendon flexibility. This increase in flexibility correlated with a decrease in pain. There was no significant difference in outcome between the sustained and intermittent stretching groups. The data suggest that both sustained and intermittent Achilles tendon stretching exercises were effective nonsurgical treatments for painful heel syndrome.